Efficacy
Tumors, tumor
TUMORS, SECONDARY, BEST, TUMOR
Fifteen patients (ORR, 50.0%; 95% CI, 31.3–68.7) achieved a confirmed objective response according to IRRC assessments, all being PR; the data met the prespecified criteria of positive results (Figure Best percentage change from baseline in target lesion size for individual patients carrying FGFR2 rearrangements. Primary and secondary efficacy endpoints
Abbreviations: CI, confidence interval; EEP, efficacy‐evaluable population; PPS, per‐protocol set; NE, not evaluable; NR, not reached; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1.Kaplan–Meier estimates of progression‐free survivalThe tumor response to pemigatinib was also confirmed by investigator assessments (Table OS data were not mature at data cutoff. One patient died. The median OS was not reached (95% CI, NE; Table 